EU Guidelines on Good Distribution Practice of Medicinal Products
The EU good distribution practice guidelines governing the procurement, holding, storage, and supply of medicinal products for human use. Issued under Directive 2001/83/EC (Articles 84 and 85b) and updated for the Falsified Medicines Directive (2011/62/EU), they set requirements for the quality system, the Responsible Person, temperature control, and supplier/customer qualification.
What this does not cover
stated in the document's own scope- Covers distribution of medicinal products for human use; distribution of active substances is addressed by separate EU GDP guidelines for active substances.
- Governs wholesale distribution, not manufacture, which is the subject of the EU GMP Guide.
- Applies to human medicines; veterinary medicine distribution is governed under Regulation (EU) 2019/6.
- Sets distribution-quality controls, not the market authorisation of the product, which follows its own EU pathway.
Always verify against the current published text before relying on it for a submission or inspection.
Overview
The EU Guidelines on Good Distribution Practice (2013/C 343/01) govern the wholesale distribution of medicinal products for human use — their procurement, receipt, holding, storage, transport and supply. They set out the quality system a distributor must operate, the requirement for a designated Responsible Person, and the controls that keep product identity, integrity and traceability intact through the supply chain, including temperature control, qualification of suppliers and customers, handling of returns, and management of falsified or recalled product. The guidelines translate the principle that a medicine’s quality, established in manufacture, must be preserved all the way to the point of supply.
Scope & applicability
Wholesale distributors and any party in the EU medicinal-product supply chain, from manufacturer release to dispensing. Extended in principle to brokers and the distribution of active substances (separate GDP for APIs applies).
Legal basis & how it acquires force
The GDP guidelines are issued under Directive 2001/83/EC, the Community code for medicinal products for human use — in particular Articles 84 and 85b, which require the Commission to publish distribution guidelines that wholesale distributors must follow as a condition of their distribution authorisation. They were revised in 2013 to reflect the Falsified Medicines Directive (2011/62/EU), which strengthened supply-chain controls against falsified medicines. Holding a wholesale distribution authorisation and complying with GDP are legal requirements for distributing medicines in the EU.
Document structure
| Part | Covers |
|---|---|
| Quality management | The quality system, outsourced activities, management review, and risk management |
| Personnel | The Responsible Person, key personnel, training, and hygiene |
| Premises and equipment | Temperature and environment control, equipment qualification, and computerised systems |
| Documentation | Records of procurement, holding and supply supporting traceability |
| Operations | Qualification of suppliers and customers, receipt, storage, picking and supply of product |
| Complaints, returns, falsified products and transport | Handling of complaints, returns, recalls, suspected falsified medicines, and controlled transport |
Key requirements
- A documented quality system with a designated Responsible Person
- Temperature-mapped storage and qualified, monitored transport
- Qualification of suppliers and customers to prevent falsified products entering the chain
- Documented handling of returns, complaints, recalls, and falsified-product suspicions
Implementation tips
- Base excursion decisions on Mean Kinetic Temperature and product stability data, not single spot readings
- Keep supplier/customer qualification evidence current — lapsed checks are a frequent GDP finding
Revision notes
Guidelines of 5 November 2013 (correcting the March 2013 version), updated to reflect the Falsified Medicines Directive 2011/62/EU.
Where this control fails
live FDA enforcementLive FDA recalls SPEQ maps to this standard’s topics — a SPEQ interpretation, not an FDA classification.
International alignment
The GDP guidelines complement the EU GMP Guide at the manufacture-to-distribution boundary and share its quality-system philosophy — GMP secures product quality during manufacture, GDP preserves it in distribution. They are reinforced by the Falsified Medicines Directive and its safety-features (unique identifier and anti-tampering) regime, and they broadly parallel the WHO and PIC/S good distribution/storage practice guidance used elsewhere.
2013/C 343/01: frequently asked questions
Quick answers to common questions about 2013/C 343/01.
What legal basis do the EU GDP guidelines have?
They are issued under Directive 2001/83/EC (Articles 84 and 85b), the Community code for human medicines. Wholesale distributors must comply with GDP as a condition of holding their distribution authorisation, so the guidelines carry practical legal force.
Who is the Responsible Person under EU GDP?
The Responsible Person is a designated individual a wholesale distributor must appoint to ensure a quality system is in place and maintained — covering areas such as GDP compliance, handling of returns and recalls, and qualification of trading partners. The role is a central requirement of the guidelines.
Why were the GDP guidelines revised in 2013?
The 2013 revision updated the guidelines to reflect the Falsified Medicines Directive (2011/62/EU), which strengthened supply-chain controls — including supplier and customer qualification and the handling of suspected falsified medicines — to keep falsified products out of the legal distribution chain.
This standard in practice
Recall domain is a SPEQ mapping of this standard’s topics, not an FDA classification.